Article Text

Download PDFPDF
7 GLP-1 cardioprotection is not mitochondrial K-ATP channel dependent
  1. JP Giblett,
  2. RJ Axell,
  3. SJ Clarke,
  4. LM McCormick,
  5. PA Read,
  6. J Reinhold,
  7. M O'Sullivan,
  8. NEJ West,
  9. PA White,
  10. DP Dutka,
  11. SP Hoole
  1. Papworth Hospital NHS Foundation Trust


Introduction Glucagon-like Peptide-1 (GLP-1) protects against left ventricular (LV) stunning but the mechanism is unclear. Two protocols (P1 and P2) investigated whether blockade of mitochondrial K-ATP channels (responsible for ischaemic conditioning) with glibenclamide abrogates GLP-1 cardioprotection in humans.

Methods P1. Patients attending for elective PCI to their LAD were assigned to 4 groups (Figure 1). Pressure-volume loops, allowing systolic/diastolic assessment, were recorded at baseline (BL1) and after 1-minute LAD balloon occlusion (BO1). GLP-1 or saline infusion was started after BO1, with loops repeated (BL2 and BO2) at 30mins. P2. Patients awaiting PCI underwent serial dobutamine stress echos (DSE) with tissue Doppler, to assess impact of GLP-1 and glibenclamide on global and regional systolic function.

Results P1. BO1 reduced LV function in all groups. Recovery from stunning (BL2) and cumulative dysfunction (BO2) improved with GLP-1 alone, and when glibenclamide was added. P2. At peak stress and recovery there was additional improvement in systolic function with GLP-1 versus control. However, systolic function was unchanged, with and without glibenclamide.

Conclusion Glibenclamide did not abrogate GLP-1-mediated cardioprotection, suggesting GLP-1 acts through a non-KATP-dependent pathway in humans.

Abstract 7 Figure 1

Illustration of changes in systolic function over time in both protocols

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.